Ask AI

Identifying and Managing Adverse Events Associated With BCMA-Directed Therapies in MM

Start Activity
Text Module
Text Module Start Activity
This activity is available for 0.50 CME/CE credit(s).

Released: August 14, 2026

Expiration: February 13, 2027

See Activity Collection

Step 1 of 5

1 Pre Assessment 2 Text Module 3 Post Assessment 4 Evaluation 5 Credit

Expert review of what oncology pharmacists need to know about how to identify and manage adverse events associated with FDA-approved BCMA-directed therapies in the treatment of patients with R/R MM, including optimizing patient outcomes by promptly identifying and effectively managing ocular toxicities of belantamab mafodotin, clinical manifestations and optimal treatment of CRS, ICANS, and infections associated with CAR T-cell therapy and/or bispecific antibodies.

Anthony Perissinotti
Anthony Perissinotti, PharmD, BCOP
AEs of BCMA Directed Agents in MM

Pre Assessment

Assess your current knowledge and clinical approach before beginning your text module.
Begin Your Text Module
1.

A 66-year-old woman was diagnosed with IgG kappa MM with t(14;16). She was initially treated with lenalidomide, bortezomib, dexamethasone, followed by autologous stem cell transplant and then lenalidomide maintenance. She experienced biochemical relapse after 5 years of maintenance therapy and received daratumumab, pomalidomide, and dexamethasone (DPd) for 1 year. Over the past several months, her M-spike slowly increased and is now >0.5 g/dL, indicating disease relapse.


Because of her lack of interest in receiving intensive treatment, she received belantamab mafodotin, bortezomib, dexamethasone. Before receiving the third dose, she presents to her community ophthalmologist for the required eye assessment. Slit-lamp exam shows grade 3 keratopathy (diffuse central microcyst-like deposits with central subepithelial haze). Her visual acuity has declined from 20/20 to 20/80 in the worse eye.


The clinical findings are: severe superficial punctate keratopathy, diffuse central corneal microcyst-like deposits, central subepithelial haze; new central stromal opacity. The ophthalmologist completes the Risk Evaluation and Mitigation Strategy (REMS) Eye Care Professional Consult Request Form, communicating a grade 3 keratopathy to the oncologist.

Which of the following is the most appropriate approach for the management of belantamab mafodotin (BM)–associated grade 3 ocular toxicity?

Begin Your Text Module